9th Annual Biomarkers Congress

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. Vasculitis UCSF Review Course January, 2010
2. Excellence in Rheumatology Scientific Advisory Board January, 2010
3. systemic vasculitis and determinants of organ targeting in vasculitis U Alabama visiting professor January, 2010
4. determinants of organ targeting in vasculitis UT- Houston Grand rounds January, 2010
5. Wegener's granulomatosis; large vessel vasculitis Harvard Review Course January, 2010
6. Vasculitis Cornell/NY Review Course January, 2010
7. Pathogenesis of vasculitis; a new way to look at an old problem Swedish Society of Rheumatology January, 2009
8. Wegener's granulomatosis and ANCA controversies Swedish Society of Rheumatology January, 2009
9. Pathogenesis of large vessel vasculitis Swedish Society of Rheumatology January, 2009
10. Macrophage migration inhibitory factor (MIF) gene polymorphism in of Wegener's granulomatosis Acta Pathologica Microbiol Immunol Scand January, 2009
11. Oral Cyclophosphamide Therapy Diminishes Ovarian Reserve in Women with Wegener's Granulomatosis. ACR January, 2009
12. Angiopoietin-2 as a Biomarker in ANCA-Associated Vasculitis. ACR January, 2009
13. The relationship between markers of platelet activation and inflammation with disease activity in Wegener's Granulomatosis ACR January, 2009
14. Frequency of Fibromyalgia , Depression and Sleep Disorders in Wegener Granulomatosis ACR January, 2009
15. Rituximab Versus Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitis: A Randomized Controlled Trial (RAVE). ACR January, 2009
16. Giant cell arteritis: A negative association with cancer? ACR January, 2009
17. Testicular vasculitis: findings differentiating isolated from systemic disease in 75 patients ACR January, 2009
18. Angiopoietin-2 as a biomarker in ANCA-associated vasculitis. Acta Pathologica Microbiol Immunol Scand. January, 2009
19. In-hospital mortality and cardiovascular outcomes in giant cell arteritis. Acta Pathologica Microbiol Immunol Scand January, 2009
20. Damage caused by Wegener's granulomatosis: data from a multicenter longitudinal cohort. Acta Pathologica Microbiol Immunol Scand. January, 2009
21. Fever in the elderly "a rheumatologist's perspective" EULAR January, 2009
22. Wegener's granulomatosis: past, present and future. Swedish Society of Rheumatology January, 2009
23. Fever in the elderly "a rheumatologist's perspective" EULAR January, 2009
24. The relationship between disease activity and markers of thrombosis and platelet activation in Wegener's granulomatosis Acta Pathologica Microbiol Immunol Scand January, 2009
25. Alpha 1-antitrypsin deficiency and risk of Wegener's granulomatosis. Acta Pathologica Microbiol Immunol Scand January, 2009
26. Treatment of Vasculitis Florida Society of Rheumatology January, 2009
27. Pathogenesis of vasculitis – are we asking the right questions? Asian Pacific League Against Rheumatism – Yokahama – Advanced Course in Rheumatology January, 2008
28. MIF Gene Polymorphism In Wegener's Granulomatosis. ACR January, 2008
29. Morbidity and Mortality of Wegener's Granulomatosis: Data from a Current Multicenter Longitudinal Cohort ACR January, 2008
30. Damage Caused by Wegener’s Granulomatosis: Data from a Multicenter Longitudinal Cohort ACR January, 2008
31. -Hospital Mortality and Cardiovascular Outcomes in Giant Cell Arteritis ACR January, 2008
32. Solid Malignancies among Patients in the Wegener’s Granulomatosis Etanercept Trial (WGET): Three and a half Years Follow-up ACR January, 2008
33. Limited utility of rapamycin in severe, refractory Wegener’s granulomatosis ACR January, 2008
34. Are ANCA-associated vasculitis and ANCA-disease useful terms for the practitioner? EULAR January, 2008
35. Tissue and serum levels of selected markers of inflammation and relapse in giant cell arteritis EULAR January, 2008
36. Minimizing the use of cyclophosphamide in Wegener's granulomatosis Norwegian Society of Rheumatology January, 2008
37. ANCA controversies Norwegian Society of Rheumatology January, 2008
38. Diagnostic issues in aortic aneurysms Norwegian Society of Rheumatology January, 2008
39. Treatment of large vessel vasculitis Norwegian Society of Rheumatology January, 2008
40. large vessel vasculitis: what we do not know and why we still do not get it right NYU - Ira Goldstein Memorial lecture January, 2008
41. ANCA controversies 9th Annual Utah Rheumatology Association Meeting January, 2008
42. Aortic root aneurysms - what they should mean to an internist and rheumatologist U Utah Medical Grand Rounds January, 2008
43. Conundrums in the field of vasculitis Hospital for Special Surgery Grand Rounds January, 2008
44. Thoracic aortic aneurysms - when do you consider vasculitis? Robert Wood Johnson SOM - GR and Visiting Professor January, 2008
45. How drugs are developed 8th International Vasculitis Symposium January, 2008
46. Differences in vascular embryology and development may determine vulnerability to inflammatory injury. EULAR Plenary Lecture January, 2008
47. Takayasu’s arteritis, still difficult to treat International GCA/PMR Conference January, 2008
48. Pathogenesis of vasculitis: new perspectives International GCA/PMR Conference January, 2008
49. Pattern differences in vasculitis – still a mystery Mayo Clinic January, 2008
50. Aortic arch aneurysms – what have we learned? Mayo Clinic January, 2008
51. Gynecologic vasculitis, an analysis of 163 patients ACR January, 2008
52. 1. Symposium on autoimmune vasculitis (moderator), 2. Rationale for treatment of giant cell arteritis; and 3. Use of anti-TNF 7th World Congress on TRAUMA, SHOCK, INFLAMMATION AND SEPSIS March, 2007
53. Large vessel vasculitis. Diagnostic Criteria Exp Rheumatol. International Vasculitis and ANCA Workshop. 2007 January, 2007
54. Substitution of methotrexate for cyclophosphamide in Wegener’s granulomatosis. A 12-year single-practice experience Clin Exp Rheumatol. International Vasculitis and ANCA Workshop January, 2007
55. Clinical and histological characterization of vasculitis involving the breast Clin Exp Rheumatol. International Vasculitis and ANCA Workshop January, 2007
56. Utility of anti-TNF agents for treatment for systemic vasculitis 7th World Congress on Trauma, Shock, Inflammation and Sepsis. January, 2007
57. Changing landscape of treatment for systemic vasculitis. 7th World Congress on Trauma, Shock, Inflammation and Sepsis. January, 2007
58. Cardiovascular outcomes in giant cell arteritis. Amer Coll Rheumatol. Arthritis Rheum. Supple January, 2007
59. Clinical and histological characterization of vasculitis involving the breast Amer Coll Rheumatol. Arthritis Rheum. Supple January, 2007
60. PTPN22 and IRF5 alleles in Wegener’s Granulomatosis Amer Coll Rheumatol. Arthritis Rheum. Supple January, 2007
61. Prevalence of alpha-1 antitrypsin deficiency in Wegener’s Granulomatosis. Amer Coll Rheumatol. Arthritis Rheum. Supple. January, 2007
62. Large vessel vasculitis - overt and occult challenges Johns Hopkins Rheumatology Review January, 2007
63. Limited Utility of Rapamycin in Severe, Refractory Wegener’s Granulomatosis (WG). Amer Coll Rheumatol. Arthritis Rheum. Supple January, 2007
64. Limited versus Severe Wegener’s Granulomatosis: Clinical outcomes and response to therapy Amer Coll Rheumatol. Arthritis Rheum. Supple. January, 2007
65. Renal Graft Survival and Patient Mortality in Wegener’s Granulomatosis (WG): A Case/Control Study Amer Coll Rheumatol. Arthritis Rheum. Supple January, 2007
66. Persistent Hematuria after Induction of Remission in Patients with Glomerulonephritis due to Wegener’s Granulomatosis Amer Coll Rheumatol. Arthritis Rheum. Supple January, 2007
67. Modern treatment of Wegener's granulomatosis Johns Hopkins Rheumatology Review January, 2007
68. Relapses in Rituximab-Treated Wegener’s Granulomatosis Patients Despite Peripheral B Cell Depletion Amer Coll Rheumatol. Arthritis Rheum. Supple January, 2007
69. 13th International Vasculitis and ANCA Workshop. January, 2007
70. Idiopathic Aortitis American College of Cardiology Annual Meeting - Symposium on Vascular Conundrums January, 2007
71. Congenital and acquired diseases of the aortic arch European League Against Rheumatism January, 2007
72. Utility and Limitations of ANCA NYU + lecture January, 2007
73. Systemic Vasculitis Special Surgery Rheumatology Review Course September, 2006
74. Vasculitis - a global approach UCSF January, 2006
75. Vasculitis Foundation Symposium January, 2006
76. intra-abdominal hemorrhage, pregnancy, vasculitis? American College of Rheumatology - CPC - vasculitis symposium January, 2006
77. treatment of vasculitis Connecticut Rheumatism Association January, 2006
78. ANCA and it's role Albany Society of Rheumatology January, 2006
79. Large vessel vasculitis and diagnostic approach to systemic vasculitis NY Academy of Medicine January, 2006
80. Durable Remission in Patients with Refractory Takayasu's Arteritis Treated with Infliximab and Etanercept ACR January, 2006
81. Reevaluation of the weighting system for the Birmingham vasculitis activity score for Wegener’s granulomatosis (BVAS/WG). ACR January, 2006
82. Adjunctive methotrexate to treat giant-cell arteritis: an individual patient data meta-analysis ACR January, 2006
83. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. ACR January, 2006
84. Wegener granulomatosis: customized treatment using cyclophosphamide and methotrexate. a 12 year single-practice experience ACR January, 2006
85. Damage in ANCA-Associated Vasculitis: Preliminary evidence for the ANCA-Associated Vasculitis Index of Damage (AVID). ACR January, 2006
86. Clinical Outcomes and Relapse Rates in Limited versus Severe Wegener’s Granulomatosis. ACR January, 2006
87. Durable remission in patients with refractory Takayasu's arteritis treated with infliximab and etanercept ACR January, 2006
88. Renal graft survival in Wegener’s granulomatosis (WG): Comparison to systemic lupus erythematosus (SLE) from a national database ACR January, 2006
89. Antineutrophil cytoplasmic antibodies against proteinase 3 do not predict disease relapses in Wegener's granulomatosis ACR January, 2006
90. Temporal artery gene expression profiles may predict conditions necessary for developing Giant Cell Arteritis ACR January, 2006
91. Effects of glucocorticoids on weight during systemic inflammation ACR January, 2006
92. GCA and Takayasu's arteritis Chicago regional vasculitis program for fellows January, 2006
93. Takayasu arteritis: guarded outcomes in an American cohort ACR January, 2006
94. Wegener granulomatosis: Customized treatment using cyclophosphamide and methotrexate. A 12 year single-practice experience ACR January, 2006
95. Biologic Therapies for Vasculitis B Cell Summit – CCF January, 2006
96. 1) ANCA – what iit means, how to use it. 2) Takayasu’s arteritis: guarded outcomes in American patients. Emory University January, 2006
97. Orbital disease in Wegener’s granulomatosis Cole Eye Institute – CCF – symposium January, 2006
98. Vasculitis Milwaukee Rheumatology Society January, 2006
99. The effects of Wegener's granulomatosis on the eye Lund Vasculitis Symposium January, 2006
100. Changing landscape of treatment for systemic vasculitis Lund Vasculitis Symposium January, 2006
101. Utility of Biologic Agents to Treat Vasculitis Harvard/MGH Rheumatology Grand Rounds January, 2006
102. Renal graft survival in Wegener's granulomatosis compared to Systemic lupus erythematosus from a National Database ACR January, 2006
103. The use of biologic therapies in the treatment of systemic vasculitis Israeli Society of Rheumatology December, 2005
104. The use of biologic therapies in systemic vasculitis and Problem solving workshop Israeli Society of Rheumatology September, 2005
105. Systemic Vasculitis. Special Surgery Rheumatology Review Course September, 2005
106. Use of Biologic Agents to Treat Systemic Vasculitis. TNF Summit and Beyond August, 2005
107. Determinants of vessel targeting in large vessel vasculitis The Pemberton Lectureship and Award January, 2005
108. Deliberations, conclusions and recommendations from recent FDA Hearings American College of Rheumatology – Spring Rheumatology Meeting – COX-2 inhibitors January, 2005
109. Risk factors for Herpes Zoster in immunocompromised patients: Experience from the Wegener’s Granulomatosis Etanercept Trial. American College of Rheumatology January, 2005
110. Solid malignancies among Wegener's granulomatosis patients treated with etanercept American College of Rheumatology January, 2005
111. The Prevalence of Signs and Symptoms of Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) in Takayasu’s Arteritis (TA). International Congress on GCA and PMR January, 2005
112. Takayasu's Arteritis (TA): Disease characteristics and outcomes in a cohort of 75 patients International Congress on GCA and PMR January, 2005
113. The treatment of giant cell arteritis with biologic agents International Congress on GCA and PMR January, 2005
114. Review of systemic vasculitis American College of Rheumatology – Spring Rheumatology Meeting January, 2005
115. Wegener's granulomatosis: past, present and future NYU Advanced Rheumatology Seminar January, 2005
116. International Giant cell arteritis workshop. Cambridge, UK January, 2005
117. Phase II study of the safety and efficacy of infliximab in Giant Cell Arteritis(GCA): 22 week interim analysis American College of Rheumatology January, 2005
118. Bench to Bedside. Treatment of Wegener’s granulomatosis Vasculitis Symposium January, 2004
119. New developments in pathogenesis and treatment of large vessel vasculitis International Congress on Autoimmunity. Budapest January, 2004
120. Wegener’s granulomatosis Association Conference January, 2004
121. New developments in pathogenesis of Giant cell arteritis and Takayasu’s arteritis NYU Advanced Rheumatology Seminar January, 2004
122. Randomized, Double-Masked, Placebo- Controlled Trial of Etanercept for the Induction and Maintenance of Remission American College of Rheumatology January, 2004
123. Association between disease activity and plasma myeloperoxidase (MPO), CRP WSR and ANCA titers in patients with Wegener‘s Granulomatosis American College of Rheumatology January, 2004
124. A Serum Proteomic Approach To Gauging The State Of Remission In Wegener’s Granulomatosis American College of Rheumatology January, 2004
125. The Prevalence of Signs and Symptoms of Polymyalgia Rheumatica and Giant Cell Arteritis in Takayasu’s Arteritis American College of Rheumatology January, 2004
126. ANCA-Status of the Wegener’s Granulomatosis Etanercept Trial (WGET) Cohort at baseline American College of Rheumatology January, 2004
127. Prospective data from the Wegener’s Granulomatosis Etanercept Trial American College of Rheumatology January, 2004
128. Takayasu’s Arteritis (TA): Disease characteristics and outcomes in a cohort of 76 patients American College of Rheumatology January, 2004
129. Comparison of disease activity measures for ANCA-Associated vasculitis. American College of Rheumatology January, 2004
130. Large vessel vasculitis: a primary autoimmune disease or a process driven by abnormalities of the vessel wall 4th International Congress on Autoimmunity January, 2004
131. Disease Relapse in Wegener's Granulomatosis During Treatment With Methotrexate. American College of Rheumatology. Annual Meeting. January, 2003
132. 13th Annual Cleveland Review of Rheumatic Diseases January, 2003
133. Utility of Anti-TNF Therapy in Takayasu’s Arteritis International Vasculitis and ANCA Workshop. January, 2003
134. Thyroid Disease In Patients with Severe Wegener’s Granulomatosis. International Vasculitis and ANCA Workshop. January, 2003
135. Association between MPO levels and disease activity in Wegener’s granulomatosis International Vasculitis and ANCA Workshop January, 2003
136. Vascular interventions in 20 patients with Takayasu’s arteritis. American College of Rheumatology. Arthritis Rheum. 48:202 January, 2003
137. High Incidence of Venous Thrombotic Events Among Patients with Wegener's Granulomatosis, for The WGET Research Group. American College of Rheumatology. Kid Blood January, 2003
138. Levels of Circulating B lymphocyte Stimulator (BLyS) are Elevated in Patients with Wegener’s Granulomatosis. American College of Rheumatology. Kid Blood January, 2003
139. Baseline Data On Patients In The Wegener’s Granulomatosis Etanercept Trial (WGET) The WGET Research Group College of Rheumatology. Kid Blood January, 2003
140. Non-approved uses of TNF blockade International Congress on Autoimmunity January, 2002
141. Genetic polymorphisms in TNF, IL-1, IL-6, and CTLA-4 in Wegener’s granulomatosis 10th International Vasculitis and ANCA Workshop. January, 2002
142. Performance of the Birmingham Vasculitis Activity Score for Wegener’s granulomatosis (BVAS/WG) in a randomized clinical trial. 10th International Vasculitis and ANCA Workshop. January, 2002
143. Effective therapy for subglottic stenosis in Wegener’s granulomatosis. 10th International Vasculitis and ANCA Workshop January, 2002
144. Anti-TNF therapy in Takayasu’s arteritis resistant to conventional therapy. 10th International Vasculitis and ANCA Workshop January, 2002
145. Nasal cavity squamous cell carcinoma in Wegener’s granulomatosis. 10th International Vasculitis and ANCA Workshop. January, 2002
146. Outcomes of vascular intervention (surgery and angioplasty) in patients with Takayasu’s arteritis 10th International Vasculitis and ANCA Workshop. January, 2002
147. 10th International Vasculitis and ANCA Workshop January, 2002
148. Inaugural Gene Hunder Lecture January, 2002
149. ACR Winter Rheumatology Symposium January, 2002
150. A giant cell arteritis-specific quality of life instrument Arthritis Rheum 44(S):57. January, 2001
151. Genetic resistance to Wegener’s Granulomatosis – a role for CCR5 in patients without antineutrophil cytoplasmic antibodies. 10th International Vasculitis and ANCA Workshop January, 2001
152. Pathogenesis of Systemic Vasculitis JFL Woodbury Lecture January, 2001
153. Giant cell arteritis Japanese Society of Rheumatology January, 2001
154. Wegener’s granulomatosis Japanese Society of Rheumatology January, 2001
155. Effective therapy for subglottic stenosis in Wegener’s granulomatosis. Arthritis Rheum 44(S):17. January, 2001
156. 1. Pathogenesis of Systemic Vasculitis; 2. Wegener’s granulomatosis; 3. Distinguishing the systemic vasculitides from each other and other diseases S January, 2001
157. Open label trial of tamoxifen in scleroderma Arthritis Rheum 44(S):1663 January, 2001
158. Modified Birmingham Vasculitis Activity Score Wegener’s Granulomatosis (BVAS/WG)-feasibility and construct validity January, 2001
159. Genetic polymorphisms in TNF, IL-1, IL-6 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) in Wegener’s granulomatosis Arthritis Rheum 44(S):344. January, 2001
160. Influence of CCR5, CCR5D32, RANTES and MIP chemokines in Wegener’s granulomatosis Arthritis Rheum 44(S):391 January, 2001
161. Pathogenesis of Systemic Vasculitis Japanese Society of Rheumatology January, 2001
162. The Tisdale Memorial Lecture January, 2000
163. Giant cell arteritis (GCA) - characterization of candidate microbial sequences and evidence of immunologic relevance Arthritis Rheum January, 2000
164. Sarcoidosis and systemic vasculitis Arthritis Rheum January, 2000
165. Etanercept in Wegener’s Granulomatosis: A Six-Month Open-Label Trial to Evaluate Safet Arthritis Rheum January, 2000
166. Modified Birmingham Vasculitis Activity Score for Wegener's granulomatosis (BVAS/WG) - feasibility and construct validity Arthritis Rheum January, 2000
167. A multicenter placebo-controlled study of methotrexate (MTX) in giant cell arteritis (GCA). Arthritis Rheum January, 2000
168. Takayasu’s arteritis: utility of magnetic resonance imaging in diagnosis and treatment Clin Exp Immunol 120 (suppl 1):118 January, 2000
169. Prevalence of antineutrophil cytoplasmic antibodies (ANCA) in patients with various pulmonary diseases or multiorgan dysfunction Clin Exp Immunol 120 January, 2000
170. Etanercept in Wegener’s granulomatosis. Results of an open label trial Arthritis Rheum 42:S January, 1999
171. Temporal occurrence of vasculitis and cancer: a report of 12 cases. Arthritis Rheum 42:S January, 1999
172. Vasculitis activity score for Wegener's granulomatosis International Network For the Study of Systemic Vasculitides (INSSYS). January, 1999
173. Prevalence of antineutrophil cytoplasmic antibodies (ANCA) in patients with various pulmonary diseases or multiorgan dysfunction Arthritis Rheum 42:S January, 1999
174. Takayasu’s arteritis: utility of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum 42:S January, 1999
175. Pathogenesis of Systemic Vasculitis Mexican Society of Rheumatology, Annual Meeting January, 1998
176. Long-term outcome of Wegener’s in patients with renal disease requiring dialysis. 8th International ANCA-Vasculitis Workshop January, 1998
177. Association of the FcgRIIIb-NA1 allele with renal disease in Wegener’s granulomatosis 8th International ANCA-Vasculitis Workshop January, 1998
178. Wegener’s granulomatosis: Patient - reported effects of disease on health, function and income 8th International ANCA-Vasculitis Workshop January, 1998
179. Vasculitis: treatment-related morbidity and mortality 8th International ANCA-Vasculitis Workshop. January, 1998
180. Systemic vasculitis. classification criteria, consensus and controversy American College of Rheumatology November, 1997
181. Management of Takayasu’s Arteritis XIXth ILAR Congress of Rheumatology January, 1997
182. Pathogenesis of ANCA-Associated Vasculitides XIXth ILAR Congress of Rheumatology January, 1997
183. Dilemmas in Vasculitis: Diagnosis and Treatment XIXth ILAR Congress of Rheumatology January, 1997
184. Recent Advances in Vasculitis XIXth ILAR Congress of Rheumatology January, 1997
185. FcgRIIIA alleles associate Wegener’s granulomatosis (WG). Biomedicine Conference January, 1997
186. Management of Takayasu’s arteritis ILAR Conference January, 1997
187. Pathogenesis of ANCA-associated vasculitides ILAR Conference January, 1997
188. Dilemmas in vasculitis: diagnosis and treatment ILAR Conference January, 1997
189. Recent advances in vasculitis ILAR Conference January, 1997
190. The Twenty-Second Annual William K. Ishmael Lectureship in Rheumatology January, 1996
191. Wegener’s Granulomatosis: The Path Traveled Since 1931 The Annual Evan’s Lecture January, 1996
192. Multicenter studies to identify improved serologic markers of active vasculitis International Conference on Takayasu Arteritis January, 1996
193. Improved MRA imaging techniques for large vessel inflammatory diseases International Conference on Takayasu Arteritis January, 1996
194. Novel magnetic resonance imaging (MRI) techniques for evaluating active arterial inflammation in Takayasu’s disease (TD). American College of Rheumatology 60th Annual Scientific Meeting January, 1996
195. Wegener’s granulomatosis (WG): Role of environmental exposures. American College of Rheumatology 60th Annual Scientific Meeting January, 1996
196. Mediastinal mass and hilar adenopathy in Wegener’s granulomatosis. International ANCA Workshop January, 1996
197. Fcg R III B alleles predict renal dysfunction in Wegener’s granulomatosis (WG). American College of Rheumatology 60th National Scientific Meeting January, 1996
198. Estradiol enhances endothelial cell attachment to extracellular matrix proteins through an increase in integrin expression American College of Rheumatology 59th Annual Scientific Meeting January, 1995
199. FcgRIIIB alleles are significantly skewed in Wegener’s granulomatosis (WG). American College of Rheumatology 59th Annual Scientific Meeting January, 1995
200. Cyclophosphamide-induced bladder toxicity in patients with Wegener’s granulomatosis. American College of Rheumatology 59th Annual Scientific Meeting January, 1995
201. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosis American College of Rheumatology 59th Annual Scientific Meeting January, 1995
202. The prevalence, epidemiology and cost of hospitalizations for vasculitis in New York State: 1986 to 1990. American College of Rheumatology 59th Annual Scientific Meeting January, 1995
203. Analysis of 42 patients with Wegener’s granulomatosis treatment with low dose methotrexate plus glucocorticoids. American College of Rheumatology 58th Annual Scientific Meeting January, 1994
204. The epidemiology of Wegener’s granulomatosis: how rare is it? American College of Rheumatology 58th Annual Scientific Meeting, 1994, Arthritis Rheum 37:S408 January, 1994
205. A study of 60 patients with Takayasu's arteritis: Presentation, treatment and long-term outcome American College of Rheumatology January, 1993
206. Treatment of Takayasu's arteritis with methotrexate American College of Rheumatology January, 1993
207. Granulomatous vasculitides and the evolving story of antineutrophil cytoplasmic antibodies American College of Rheumatology January, 1993
208. A longterm prospective study of Wegener's granulomatosis in 23 children and adolescents: clinical presentation and outcome. American College of Rheumatology, National Meeting January, 1992
209. The management of subglottic stenosis in Wegener's granulomatosis Eastern Section of The Triological Society January, 1992
210. Limited prognostic value of the antineutrophil cytoplasmic antibody (C-ANCA) in patients with Wegener's granulomatosis The 4th International Workshop on ANCA. The 2nd International Colloquium on Wegener's granulomatosis and vasculitic disorders January, 1992
211. Treatment of the vasculitides. State of the Art The 2nd International Colloquium on Wegener's Granulomatosis and Vasculitic Disorders. January, 1992
212. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. American College of Rheumatology, National Meeting, Arthritis Rheum 36 January, 1992
213. Haptoglobin-stimulation of angiogenesis in the systemic vasculitides. American College of Rheumatology, National Meeting, Arthritis Rheum 34:S117 January, 1991
214. Treatment of Takayasu's arteritis with methotrexate. American College of Rheumatology, National Meeting, Arthritis Rheum 34:S74 January, 1991
215. Wegener's granulomatosis: Permanent disease morbidity in 158 patients N.E. Regional American College of Rheumatology Meeting, National Meeting, Arthritis Rheum 34:S74 January, 1991
216. Estradiol increases leukocyte adhesion to TNF-stimulated endothelial cell monolayers: Implications for the pathogenesis of Takayasu's arteritis American Federation of Clinical Research, American College of Rheumatology, Arthritis Rheum 34:S169 January, 1991
217. Surgical pathology of the lung in Wegener's granulomatosis. International Conference Supplement, Am Rev Resp Dis 143:A220 January, 1991
218. Pulse cyclophosphamide therapy for Wegener's granulomatosis International Society for Rheumatic Therapy, London, England January, 1990
219. Human macrophages express endothelins - novel cytokines with vasoactive properties. Second International Conference on Endothelin, Japan. J Vasc Med Biol 2:177 January, 1990
220. IgG antineutrophil cytoplasmic antibodies are produced in the respiratory tract of patients with Wegener's granulomatosis Arthritis Rheum 33:6S January, 1990
221. Treatment of systemic vasculitides with intermittent high dose intravenous cyclophosphamide Arthriris Rheum 33:14S January, 1990
222. Interpretation of head and neck biopsies in Wegener's granulomatosis Modern Pathol 2:24A January, 1989
223. Gastrointestinal emergencies. Vasculitis and the gut Holland Digestive Disease Week January, 1989
224. Anti-neutrophil cytoplasmic antibodies in Wegener's granulomatosis Am J Clin Pathol 92:557 January, 1989
225. Bronchoalveolar lavage in Wegener's granulomatosis. Arthritis Rheum 32:S125 January, 1989
226. Experience with surgical treatment for Takayasu's disease. Eastern Vascular Society January, 1988
227. Pelvic and hip girdle tumors as a cause of hip pain Northeast Regional ARA Meeting January, 1986
228. Hypoparathyroidism due to progressive systemic sclerosis N.E. Regional Meeting, ARA January, 1986
229. Presentation, treatment and prognosis of idiopathic inflammatory muscle disease in a rural hospital Arthritis Rheum 26:568 January, 1983
230. Calcium oxalate microcrystalline arthritis in chronic renal failure Arthritis Rheum 24:573, 1981. January, 1981
231. Septic arthritis associated with Mycobacterium avium: Case report and literature review. XIV International Congress of Rheumatology January, 1977
232. Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210 Proc Amer Assoc of Cancer Res 9:31, 1968 January, 1968



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
B: Vasculitis 2012 UCSF Rheumatology Board Review and Clinical Update August, 2012
Vasculitis 2012 UCSF Rheumatology Board Review and Clinical Update August, 2012
PARALLEL HALL 1 | Small Vessel Vasculitis: the future for clinical care Excellence in Rheumatology January, 2012
PARALLEL HALL 1 | CONCURRENT SESSION | "VASCULITIS" Excellence in Rheumatology January, 2012
Vasculitis : A Global Approach 2010 UCSF Rheumatology Board Review and Clinical Update August, 2010
Vasculitis: A Global Approach 2009 UCSF Rheumatology Board Review September, 2009

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.